Business
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple key brain regions, including key Alzheimer’s disease-associated regions, most notably in the hippocampusReduction in hippocampal neuroinflammation, meas
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Joshua Hare","length":11,"tagName":"p"},{"type":"image","alt":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","displaySize":"","headline":null,"caption":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":109,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GiloV_.I1LiY.7J9ReDotg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8","width":109,"height":119}}},{"type":"list","items":[{"val":[{"type":"text","content":"Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple key brain regions, including key Alzheimer’s disease-associated regions, most notably in the hippocampus","length":342,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduction in hippocampal neuroinflammation, measured using MRI assessed free water, correlated strongly with preservation of hippocampal volume and with clinical outcomes","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings suggest a sustained anti-inflammatory effect of laromestrocel, reinforcing its proposed mechanism of action in the treatment of mild Alzheimer's disease","length":165,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":677,"olType":false},{"type":"text","content":"MIAMI, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cell...